The BILAG-2004 index is associated with development of new damage in SLE

Author:

Yee Chee-Seng1ORCID,Gordon Caroline2ORCID,Akil Mohammed3,Lanyon Peter4,Edwards Christopher J5,Isenberg David A6ORCID,Rahman Anisur6ORCID,Teh Lee-Suan78ORCID,Tosounidou Sofia9,Stevens Robert1,Prabu Athiveeraramapandian2,Griffiths Bridget10,McHugh Neil11ORCID,Bruce Ian N12ORCID,Ahmad Yasmeen13,Khamashta Munther A14,Farewell Vernon T15

Affiliation:

1. Department of Rheumatology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust , Doncaster

2. Rheumatology Research Group, Institute of Inflammation of Ageing, University of Birmingham , Birmingham

3. Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust , Sheffield

4. Department of Rheumatology, Nottingham University Hospitals NHS Trust , Nottingham

5. Musculoskeletal Research Unit, NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust , Southampton

6. Centre For Rheumatology, Division of Medicine, University College London , London

7. Department of Rheumatology, Royal Blackburn Teaching Hospital , Blackburn

8. Faculty of Clinical and Biomedical Sciences, University of Central Lancashire , Preston

9. Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust , Birmingham

10. Department of Rheumatology, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne

11. Department of Pharmacy and Pharmacology, University of Bath , Bath

12. Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester

13. Department of Rheumatology, Betsi Cadwaladr University Health Board , Wales

14. Women & Children's Health, King’s College London , London

15. MRC Biostatistics Unit, Universtiy of Cambridge , Cambridge, UK

Abstract

Abstract Objective To determine whether BILAG-2004 index is associated with the development of damage in a cohort of SLE patients. Mortality and development of damage were examined. Methods This was a multicentre longitudinal study. Patients were recruited within 12 months of achieving fourth ACR classification criterion for SLE. Data were collected on disease activity, damage, SLE-specific drug exposure, cardiovascular risk factors, antiphospholipid syndrome status and death at every visit. This study ran from 1 January 2005 to 31 December 2017. Descriptive statistics were used to analyse mortality and development of new damage. Poisson regression was used to examine potential explanatory variables for development of new damage. Results A total of 273 SLE patients were recruited with total follow-up of 1767 patient-years (median 73.4 months). There were 6348 assessments with disease activity scores available for analysis. During follow-up, 13 deaths and 114 new damage items (in 83 patients) occurred. The incidence rate for development of damage was higher in the first 3 years before stabilizing at a lower rate. Overall rate for damage accrual was 61.1 per 1000 person-years (95% CI: 50.6, 73.8). Analysis showed that active disease scores according to BILAG-2004 index (systems scores of A or B, counts of systems with A and BILAG-2004 numerical score) were associated with development of new damage. Low disease activity (LDA) states [BILAG-2004 LDA and BILAG Systems Tally (BST) persistent LDA] were inversely associated with development of damage. Conclusions BILAG-2004 index is associated with new damage. BILAG-2004 LDA and BST persistent LDA can be considered as treatment targets.

Funder

Versus Arthritis

Medical Research Council

Vifor Pharma

Aspreva Pharmaceuticals

NIHR

Manchester Biomedical Research Unit

Manchester Wellcome Trust Clinical Research Facility

National Institute for Health Research University College London Hospitals Biomedical Research Centre

The Birmingham SLE

West Birmingham Hospitals

NHS

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3